About the Company
G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GTHX News
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.8, along with a high estimate of $14.00 and a low estimate of $4.00. Surpassing the ...
G1 Therapeutics Inc GTHX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
Analyst Gil Blum of Needham maintained a Buy rating on G1 Therapeutics (GTHX – Research Report), retaining the price target of $12.00.
G1 Therapeutics Stock (NASDAQ:GTHX), Quotes and News Summary
Follow G1 Therapeutics as it advances trilaciclib in ... Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than ...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options ...
G1 Therapeutics, Inc. (GTHX)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
G1 Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
G1 Therapeutics Inc (GTHX)
G1 Therapeutics, Inc. (NASDAQ:GTHX) Chief Financial Officer, John W. V Umstead, recently sold shares of the company's stock, according to a new SEC filing. The transaction, which ...
G1 Therapeutics Inc (GTHX)
G1 Therapeutics Inc. (NASDAQ:GTHX) jumped $4.75, or 24%, to $24.50 on 2.2 million... Arrowhead Pharmaceuticals, Inc. (ARWR) ARWR had a breakout of a 6-day flag on Tuesday with a breakaway gap ...
Loading the latest forecasts...